CD40-activated B cells as antigen-presenting cells: The final sprint toward clinical application

Expert Review of Vaccines

Volumn 12, Issue 6, 2013, Pages 631-637

  Wennhold, Kerstin ^a   Shimabukuro Vornhagen, Alexander ^a   Theurich, Sebastian ^a   Von Bergwelt Baildon, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

APC; cancer immunotherapy; CD40 activated B cell; cellular adjuvant

Indexed keywords

CANCER VACCINE; CD40 LIGAND; CHEMOKINE; TUMOR ANTIGEN; CD40 ANTIGEN; CYTOKINE;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL STIMULATION; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; HUMAN; LYMPHOID ORGAN; MEMORY T LYMPHOCYTE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION; ANIMAL; CD8+ T LYMPHOCYTE; DOG; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; PROCEDURES; SECRETION (PROCESS);

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DOGS; HUMANS; LYMPHOCYTE ACTIVATION; MICE; VACCINATION;

EID: 84879062189     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.39     Document Type: Review

References (68)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991).
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998). (Pubitemid 28155090)
3. Linch DC, Devereux S. Monocyte-derived dendritic cells do not proliferate and are not susceptible to retroviral transduction. Br. J. Haematol. 108(4), 817-824 (2000). (Pubitemid 30304515)
4. Draube A, Klein-González N, Mattheus S et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE 6(4), e18801 (2011).
5. Martín-Fontecha A, Sebastiani S, Höpken UE et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. 198(4), 615-621 (2003). (Pubitemid 37040395)
6. Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 157(4), 1406-1414 (1996). (Pubitemid 126449077)
7. Hackstein H, Morelli AE, Thomson AW. Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol. 22(8), 437-442 (2001). (Pubitemid 32709978)
8. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2(3), 151-161 (2002). (Pubitemid 37336516)
9. Barrat-Boyes SM, Zimmer MI, Harshyne LA et al. Maturation and trafficking of monocyte-dervied dendritic cells in mokeys: implications for dendritic cell-based vaccines. J. Immunol. 164(5), 2487-2495 (2000). (Pubitemid 30115478)
10. Breukels MA, Rijkers GT, Voorhorst-Ogink MM, Zegers BJ. Regulatory T cells in the antibody response to Haemophilus influenzae type b polysaccharide. Infect. Immun. 67(2), 789-793 (1999). (Pubitemid 29059219)
11. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int. J. Antimicrob. Agents 32(3), 199-206 (2008).
12. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 265(5177), 1385-1387 (1994). (Pubitemid 24306785)
13. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type B conjugate vaccines. Immunology 113(2), 163-174 (2004). (Pubitemid 39312443)
14. Lenschow DJ, Sperling AI, Cooke MP et al. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J. Immunol. 153(5), 1990-1997 (1994). (Pubitemid 24256668)
15. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 177(4), 925-935 (1993). (Pubitemid 23097382)
16. Evans DE, Munks MW, Purkerson JM, Parker DC. Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40. J. Immunol. 164(2), 688-697 (2000). (Pubitemid 30043689)
17. Kennedy MK, Mohler KM, Shanebeck KD et al. Induction of B cell costimulatory function by recombinant murine CD40 ligand. Eur. J. Immunol. 24(1), 116-123 (1994). (Pubitemid 24014686)
18. Faassen AE, Dalke DP, Berton MT, Warren WD, Pierce SK. CD40-CD40 ligand interactions stimulate B cell antigen processing. Eur. J. Immunol. 25(12), 3249-3255 (1995). (Pubitemid 26004925)
19. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 222, 357-368 (2008). (Pubitemid 351430366)
20. Banchereau J, de Paoli P, Vallé A, Garcia E, Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251(4989), 70-72 (1991). (Pubitemid 21916853)
21. Banchereau J, Rousset F. Growing human B lymphocytes in the CD40 system. Nature 353(6345), 678-679 (1991).
22. Neron S, Nadeau PJ, Darveau A, Leblanc JF. Tuning of CD40-CD154 interactions in human B lymphocyte activation: a broad array of in vitro models for a complex in vivo situation. Arch. Immunol. Ther. Exp. (Warzs.) 59(1), 25-40 (2011).
23. Yoon SH, Cho HI, Kim TG. Activation of B cells using Schneider 2 cells expressing CD40 ligand for the enhancement of antigen presentation in vitro. Exp. Mol. Med. 37(6), 567-574 (2005).
24. Schultze JL, Cardoso AA, Freeman GJ et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl Acad. Sci. USA 92(18), 8200-8204 (1995).
25. Fournel S, Wieckowski S, Sun W et al. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat. Chem. Biol. 1(7), 377-382 (2005).
26. Ivanov R, Aarts T, Hagenbeek A, Hol S, Ebeling S. B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC. Cytotherapy 7(1), 62-73 (2005). (Pubitemid 40542405)
27. Kilinc MO, Mukundan L, Yolcu ES, Singh NP, Suttles J, Shirwan H. Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon. Exp. Mol. Pathol. 80(3), 252-261 (2006). (Pubitemid 44255613)
28. Schultze JL, Michalak S, Seamon MJ et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 100(11), 2757-2765 (1997). (Pubitemid 28007544)
29. Liebig TM, Fiedler A, Klein-Gonzalez N, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. Murine model of CD40-activation of B cells. J. Vis. Exp. 37, p 1734 (2010).
30. Liebig TM, Fiedler A, Zoghi S, Shimabukuro-Vornhagen A, von Bergwelt-Baildon MS. Generation of human CD40-activated B cells. J. Vis. Exp. 32, p. 1373 (2009).
31. Mayr C, Speicher MR, Kofler DM et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107(2), 742-751 (2006). (Pubitemid 43076401)
32. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99(9), 3319-3325 (2002). (Pubitemid 34525313)
33. Wiesner M, Zentz C, Mayr C et al. Conditional immortalization of human B cells by CD40 ligation. PLoS ONE 3(1), e1464 (2008).
34. Tretter T, Venigalla RK, Eckstein V et al. Induction of CD4+ T-cell anergy and apoptosis by activated human B cells. Blood 112(12), 4555-4564 (2008).
35. Tu W, Lau YL, Zheng J et al. Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells. Blood 112(6), 2554-2562 (2008).
36. Shimabukuro-Vornhagen A, Kondo E, Liebig T, von Bergwelt-Baildon M. Activated human B cells: stimulatory or tolerogenic antigen-presenting cells Blood 114(3), 746-747; author reply 747 (2009).
37. Kondo E, Topp MS, Kiem HP et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J. Immunol. 169(4), 2164-2171 (2002). (Pubitemid 34857684)
38. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigenpresenting cells that can generate specific T cells. Cancer Res. 63(11), 2836-2843 (2003). (Pubitemid 36667155)
39. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103(6), 2046-2054 (2004). (Pubitemid 38326219)
40. Ahmadi T, Flies A, Efebera Y, Sherr DH. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class Iand class II-binding peptides. Immunology 124(1), 129-140 (2008). (Pubitemid 351537580)
41. Wu C, Liu Y, Zhao Q et al. Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: a preliminary approach for anti-HBV immunotherapy. Virol. J. 7(1), 370 (2010).
42. Shen S, Xu Z, Qian X, Ding Y, Yu L, Liu B. Autogeneic RNA-electroporated CD40-ligand activated B-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo. Exp. Oncol. 29(2), 137-143 (2007). (Pubitemid 47310509)
43. von Bergwelt-Baildon M, Schultze JL, Maecker B et al. CD40 stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 63(11), 2836-2543 (2003).
44. Theurich S, Malcher J, Becker HJ et al. Activated primary human B cells efficiently induce early CD40L and CD107a expression in CD4+ T cells. Blood 118(22), 5979-5980 (2011).
45. Liljedahl M, Winqvist O, Surh CD et al. Altered antigen presentation in mice lacking H2-O. Immunity 8(2), 233-243 (1998). (Pubitemid 28123750)
46. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 3(11), 867-878 (2003). (Pubitemid 37411716)
47. von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 107(7), 2786-2789 (2006).
48. Guo S, Xu J, Denning W, Hel Z. Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen. Gene Ther. 16(11), 1300-1313 (2009).
49. Klein-Gonzalez N, Balkow S, Kondo E et al. CD40-activated B-cells migrate towards secondary lymphoid organs and interact dynamically with T-cells. Presented at: 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, 21-24 March 2010.
50. Gunzer M, Weishaupt C, Hillmer A et al. A spectrum of biophysical interaction modes between T cells and different antigen-presenting cells during priming in 3-D collagen and in vivo. Blood 104(9), 2801-2809 (2004). (Pubitemid 39434965)
51. Ritchie DS, Yang J, Hermans IF, Ronchese F. B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T-cells. Scand. J. Immunol. 60(6), 543-551 (2004). (Pubitemid 39665099)
52. Liebig T, Shimabukuro-Vornhagen A, Samir-Ghali, von Bergwelt-Baildon M. In vivo evaluation of a CD40-activated B cell-based tumor vaccine for use in cellular immunotherapy. Presented at: CIMT 9th Annual Meeting, Mainz, Germany, 25-27 May 2011.
53. Sabat R, Grütz G, Warszawska K et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 21(5), 331-344 (2010).
54. Steinbrink K, Jonuleit H, Müller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 93(5), 1634-1642 (1999). (Pubitemid 29102491)
55. Yang L. TGFbeta, a potent regulator of tumor microenvironment and host immune response, implication for therapy. Curr. Mol. Med. 10(4), 374-380 (2010).
56. Geissmann F, Revy P, Regnault A et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 162(8), 4567-4575 (1999). (Pubitemid 29314856)
57. Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin. Biol. Ther. 7(4), 449-460 (2007). (Pubitemid 46524672)
58. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096-1103 (1996). (Pubitemid 26338628)
59. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendriticcell defects. Nat. Rev. Immunol. 4(12), 941-952 (2004). (Pubitemid 39620069)
60. Shimabukuro-Vornhagen A, Draube A, Liebig TM, Rothe A, Kochanek M, von Bergwelt-Baildon MS. The immunosuppressive factors IL-10, TGF-ß, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J. Exp. Clin. Cancer Res. 31, 47 (2012).
61. Sorenmo KU, Krick E, Coughlin CM et al. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS ONE 6(8), e24167 (2011).
62. Kondo E, Maecker B, Weihrauch MR et al. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin. Cancer Res. 14(20), 6574-6579 (2008).
63. Li Q, Lao X, Pan Q et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 17(15), 4987-4995 (2011).
64. Kugler A, Seseke F, Thelen P et al. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br. J. Urol. 82(4), 487-493 (1998). (Pubitemid 28477287)
65. Naito M, Hainz U, Burkhardt UE et al. CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol. Immunother. 62(2), 347-357 (2013).
66. Kondo E, Gryschok L, Schultze JL, von Bergwelt-Baildon MS. Using CD40-activated B cells to efficiently identify epitopes of tumor antigens. J. Immunother. 32(2), 157-160 (2009).
67. Fujiwara H, Melenhorst JJ, El Ouriaghli F et al. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin. Cancer Res. 11(12), 4495-4503 (2005). (Pubitemid 40825640)
68. Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int. J. Cancer 115(2), 333-336 (2005). (Pubitemid 40586746)